performed the experiments and analyzed the data; T.A., M.H. regulated by tau. Immunohistochemical and biochemical analyses demonstrate that protein levels of PN components differ between TauP301LHET-brains of AD patients revealed that areas with a high-density of PN-associated neurons are less severely affected by tau pathology compared to areas with sparse quantity of S0859 PN-positive neurons. Furthermore, PN-associated neurons appear to be virtually devoid of neurofibrillary tangles (NFTs) even in advanced stages of AD [22,35,36,37], leading to the assumption that PNs serve neuroprotective functions. In a series of follow-up studies the CSPG aggrecan was recognized to be the carrier of this function [38,39]. However, the biological basis for the selective vulnerability of neurons in tauopathies and the relation to neuroprotection by aggrecan remains elusive. In a previous work, we generated the TauP301L-mouse [40] by crossbreeding TauP301L mice [41,42] and heterozygous aggrecan mice [43,44,45] with the aim to gain more knowledge around the mechanisms of the neuroprotective action of aggrecan against tau induced pathology. All offsprings revealed one allele of murine tau and one allele of P301L human tau and either one or two S0859 alleles of functional aggrecan. The deficit of one functional aggrecan allele in the heterozygous aggrecan genotype was linked to a ~60% reduction of aggrecan protein level [40]. Though both genotypes of this mouse were genetically identical with respect to the P301L mutation of tau and murine tau, we surprisingly detected that the total protein amount of transgenic human P301L tau as well as endogenous murine tau was significantly increased in the heterozygous aggrecan genotype compared to the wildtype aggrecan genotype in this mouse model, confirming a regulatory effect of aggrecan on tau expression and indicating a more severe tauopathy when aggrecan is usually reduced [40]. Interestingly, tauopathies as well as A-pathologies have been linked to significant changes in general PN structure and protein expression [46,47]. Further, sulfated proteoglycans were shown to bind to tau protein and directly influence tau distributing, S0859 uptake, and aggregation [48,49]. These findings might also show a mutual conversation of tau and proteoglycans of PNs and raise the assumption that tau protein might have the potential to directly control the formation and mature structure of perineuronal nets. In the present study, we resolved this hypothesis by investigating the structure and protein expression of PNs in mice with different levels of tau expression. As pathological tau species propagate extracellularly and are supposed to spread trans-synaptically through anatomically connected networks [50,51], we further investigated the potential of PN components to actually interact with tau. 2. Materials and Methods 2.1. Animals All experiments were carried out in (1) wildtype aggrecan mice with two functional aggrecan alleles (strain: mice, further termed mice with either two or one functional aggrecan alleles (TauP301L-mice [40] were generated by crossbreeding of heterozygous mice (strain: for 10 min at 4 C, the supernatants were recovered, and total protein concentration was decided using BCA kit (Pierce, Rockford, IL, Rabbit Polyclonal to MBTPS2 USA). 2.4. Western Blot Equal amounts of protein extracts were separated under reducing and denaturating conditions on SDS-PAGE and transferred to a polyvinylidene difluoride membrane (GE Healthcare, Freiburg, Germany) overnight at 25 V. Blots were incubated with blocking answer (1% BSA in TBS-T (0.05% Tween 20)) for 1 h and probed overnight at 4 C with the primary antibody diluted in blocking solution (Table 1). Blots were washed 3 times with TBS-T followed by incubation with appropriate peroxidase-conjugated secondary antibodies for 1 h. HRP activity was visualized by means of chemoluminescence reagent (Lumigen ECL Ultra, Lumigen Inc., Southfield, MI, USA) and imaged with a chemoluminescence detection system (Fusion FX, Vilber, Lourmat, Eberhardzell, Germany). Quantification was performed on initial data files. Ratios of optical density were determined by means of TotalLab v2005 (Nonlinear Dynamics, Newcastle upon Tyne, UK) and S0859 normalized to total protein content of each lane stained by Coomassie R250 [60]. 2.5. Enzyme-Linked Immunosorbent Assay (ELISA) For the detection of HA, high binding microplates (Greiner Bio-One GmbH, Frickenhausen, Germany) were coated overnight at 4 C with 50 L brain homogenates (5 mg/mL) 1:4000 diluted in carbonate buffer (0.1 M NaCO3, pH 9.7). Coated plates were S0859 washed with TBS-T (0.05% Tween 20) and incubated with blocking solution (1% BSA in TBS-T) for 1 h and probed with biotinylated hyaluronic acid binding protein (Merck Millipore, Darmstadt, Germany,.